Seres therapeutics announces first patient enrolled in phase 1b study of ser-155, an investigational microbiome therapeutic to reduce the risk of antibiotic-resistant bacterial infections and graft-versus-host disease (gvhd)

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announced today that the first patient has been enrolled in the ser-155 phase 1b study. ser-155 is an investigational, oral, cultivated microbiome therapeutic. the consortia is a rationally-designed selection of bacteria optimized to enhance desired pharmacological properties to reduce the incidence of gastrointestinal bacterial infections, bacteremia and graft-versus-host dise
MCRB Ratings Summary
MCRB Quant Ranking